Dr. Sharretts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10903 New Hampshire Ave
Silver Spring, MD 20993
Summary
- Dr. John Sharretts is Director of the Division of Diabetes, Lipid Disorders, and Obesity (DDLO) at the US Food and Drug Administration (FDA). He joined FDA in 2015, and previously served as Team Leader and Deputy Division Director. DDLO is part of the Office of New Drugs within the Center for Drug Evaluation and Research at FDA. Dr. Sharretts is trained as an endocrinologist. Prior to joining FDA, he was clinical assistant professor at the University of Pennsylvania and the Philadelphia VA Medical Center. He completed his medical degree at Virginia Commonwealth University School of Medicine in 1994, completed residency in Internal Medicine at MedStar Health/Georgetown-Washington Hospital Center in 1998 and chief residency in 1999, and completed fellowship in Diabetes, Endocrinology, and Metabolism at the National Institutes of Health Clinical Center in 2011. He has contributed to several published studies, with notable works appearing in respected journals such as The New England Journal of Medicine.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2008 - 2011
- MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 1995 - 1999
- Greater Baltimore Medical CenterInternship, Transitional Year, 1994 - 1995
- Virginia Commonwealth University School of MedicineClass of 1994
Certifications & Licensure
- DC State Medical License 1997 - 2027
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 5 citationsShould responder analyses be conducted on continuous outcomes?Robert Abugov, Jennifer Clark, Laura Higginbotham, Feng Li, Lei Nie
Pharmaceutical Statistics. 2023-03-01 - 73 citationsCancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 TrialJohn Sharretts, Ovidiu Galescu, Shanti Gomatam, Eugenio Andraca-Carrera, Christian Hampp
The New England Journal of Medicine. 2020-09-09 - 7 citationsClinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1.Sakshi Jhawar, Rahul Lakhotia, Mari Suzuki, James Welch, Sunita K. Agarwal
Endocrinology, Diabetes & Metabolism Case Reports. 2019-08-20
Press Mentions
- Novo’s Semaglutide Scores in Liver Fibrosis and MASH TrialNovember 4th, 2024
- FDA Approves Tirzepatide for Treating ObesityNovember 9th, 2023
- Wegovy vs. Ozempic: The Truth About These New Weight-Loss DrugsApril 6th, 2023
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: